Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
We have treated 113 patients with zidovudine since its licensure, 80 with acquired immunodeficiency syndrome and 33 with acquired immunodeficiency syndrome-related complex. This paper reports on the efficacy and toxicity observed in these patients. Improved well-being, reduced frequency and severity of opportunist infections were notable in the first year of follow-up. More rapid improvement in pulmonary physiological tests during recovery from Pneumocystis carinii pneumonia was also observed in treated patients. Patients with lower initial platelet counts showed early increases in platelet counts. There was a consistent fall in human immunodeficiency virus (HIV) p24 antigen during treatment, although not always to undetectable levels. CD4 cell counts showed a rise in the first months of treatment but these were not sustained, despite continuing clinical benefit. Neuropsychological and clinical evidence of benefit in HIV encephalopathy are described. We have analysed the factors influencing marrow toxicity and have found that low CD4 count and the intercurrent use of ganciclovir and dapsone increase myelotoxicity. We describe the clinical and biochemical features of the myopathy associated with long-term use of zidovudine and summarise our findings on dose-reduction associated meningo-encephalitis.
Pinching
A J
AJ
Department of Immunology and Medicine, St Mary's Hospital and Medical School, London, U.K.
Helbert
M
M
Peddle
B
B
Robinson
D
D
Janes
K
K
Gor
D
D
Jeffries
D J
DJ
Stoneham
C
C
Mitchell
D
D
Kocsis
A E
AE
D000386:AIDS-Related Complex / Q000150:complications / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000212:Acyclovir / Q000009:adverse effects / Q000031:analogs & derivatives; D001853:Bone Marrow / Q000187:drug effects; D001927:Brain Diseases / Q000188:drug therapy / Q000209:etiology; D003622:Dapsone / Q000009:adverse effects; D015774:Ganciclovir; D015488:HIV Antigens / Q000032:analysis; D016655:HIV Core Protein p24; D006801:Humans; D008590:Meningoencephalitis / Q000209:etiology; D009135:Muscular Diseases / Q000139:chemically induced; D009483:Neuropsychological Tests; D009894:Opportunistic Infections / Q000150:complications; D012129:Respiratory Function Tests; D012191:Retroviridae Proteins / Q000032:analysis; D013601:T-Lymphocytes; D006377:T-Lymphocytes, Helper-Inducer; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
D015488:HIV Antigens; D016655:HIV Core Protein p24; D012191:Retroviridae Proteins; D015215:Zidovudine; D003622:Dapsone; D015774:Ganciclovir; D000212:Acyclovir